Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice

Abstract

Background:

Characteristics at clinically isolated syndrome (CIS) examination assist in identification of patient at highest risk of early second attack and could benefit the most from early disease-modifying drugs (DMDs).

Objective:

To examine determinants of second attack and validate a prognostic nomogram for individualised risk assessment of clinical conversion.

Methods:

Patients with CIS were prospectively followed up in the MSBase Incident Study. Predictors of clinical conversion were analysed using Cox proportional hazards regression. Prognostic nomograms were derived to calculate conversion probability and validated using concordance indices.

Results:

A total of 3296 patients from 50 clinics in 22 countries were followed up for a median (inter-quartile range (IQR)) of 1.92 years (0.90, 3.71). In all, 1953 (59.3%) patients recorded a second attack. Higher Expanded Disability Status Scale (EDSS) at baseline, first symptom location, oligoclonal bands and various brain and spinal magnetic resonance imaging (MRI) metrics were all predictors of conversion. Conversely, older age and DMD exposure post-CIS were associated with reduced rates. Prognostic nomograms demonstrated high concordance between estimated and observed conversion probabilities.

Conclusion:

This multinational study shows that age at CIS onset, DMD exposure, EDSS, multiple brain and spinal MRI criteria and oligoclonal bands are associated with shorter time to relapse. Nomogram assessment may be useful in clinical practice for estimating future clinical conversion.

Keywords

Nomogram clinically isolated syndrome clinically definite multiple sclerosis second attack disease-modifying drugs MRI CSF MS CIS

Get full access to this article

View all access options for this article.

References

Barkhof

Filippi

Miller

et al . Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059–2069.

Miller

Barkhof

Montalban

et al . Clinically isolated syndromes suggestive of multiple sclerosis, part I: Natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005; 4(5): 281–288.

Tintore

Rovira

Rio

et al . Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67: 968–972.

Korteweg

Tintore

Uitdehaag

et al . MRI criteria for dissemination in space in patients with clinically isolated syndromes: A multicentre follow-up study. Lancet Neurol 2006; 5: 221–227.

Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65(6): 727.

Novakova

Skoog

Runmarker

et al . Clinically isolated syndromes with no further disease activity suggestive of multiple sclerosis at the age of population life expectancy. Mult Scler 2014; 20: 496–500.

Margolis

Fowler

Johnson

et al . Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: A retrospective cohort study. BMC Neurol 2011; 11(1): 122.

Marcus

Waubant

. Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist 2013; 3(2): 65–80.

Freedman

Blumhardt

Brochet

et al . International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler 2002; 8(1): 19–23.

10.

D’Alessandro

Vignatelli

Lugaresi

et al . Risk of multiple sclerosis following clinically isolated syndrome: A 4-year prospective study. J Neurol 2013; 260(6): 1583–1593.

11.

Sandberg-Wollheim

Olsson

. Cerebrospinal fluid oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: Yes. Mult Scler 2013; 19(6): 714–716.

12.

Comi

Martinelli

Rodegher

et al . Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet 2009; 374(9700): 1503–1511.

13.

Kappos

Freedman

Polman

et al . Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370(9585): 389–397.

14.

Beck

Chandler

Cole

et al . Interferon β-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002; 51(4): 481–490.

15.

Comi

Filippi

Barkhof

et al . Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 2001; 357(9268): 1576–1582.

16.

Polman

Reingold

Banwell

et al . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69(2): 292–302.

17.

CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002; 59(7): 998.

18.

Tintore

Rovira

Rio

et al . Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008; 70(13 Part. 2): 1079–1083.

19.

Kuhle

Disanto

Dobson

et al . Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler 2015; 21: 1013–1024.

20.

Andersson

Alvarez-Cermeno

Bernardi

et al . Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. J Neurol Neurosurg Psychiatry 1994; 57(8): 897–902.

21.

Freedman

Thompson

Deisenhammer

et al . Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: A consensus statement. Arch Neruol 2005; 62(6): 865–870.

22.

Dobson

Ramagopalan

Davis

et al . Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: A meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 2013; 84(8): 909–914.

23.

Tintore

Rovira

Río

et al . Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015; 138(7): 1863–1874.

24.

Butzkueven

Chapman

Cristiano

et al . MSBase: An international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 2006; 12: 769–774.

25.

Tintoré

Rovira

Martínez

et al . Isolated demyelinating syndromes: Comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000; 21(4): 702–706.

26.

Polman

Reingold

Edan

et al . Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol 2005; 58(6): 840–846.

27.

Poser

Paty

Scheinberg

et al . New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13(3): 227–231.

28.

Kattan

Leung

Brennan

. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002; 20(3): 791–796.

29.

Swanton

Rovira

Tintoré

et al . MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: A multicentre retrospective study. Lancet Neurol 2007; 6: 677–686.

30.

Comi

De Stefano

Freedman

et al . Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): A phase 3 randomised controlled trial. Lancet Neurol 2012; 11(1): 33–41.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.65 MB

0.21 MB

0.65 MB

0.21 MB